Crinetics Pharmaceuticals
CRNX
Market cap $4.78B

53.14 USD

+1.36

2.63%

At close Oct 11, 4:00 PM EDT

After hours

53.00

-0.14

0.26%

1 day

2.63%

5 days

-0.17%

1 month

4.73%

3 months

0.62%

6 months

10.64%

Year to date

50.16%

1 year

95.73%

5 years

222.45%

About: Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

Employees: 210

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

200% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 16

74% more repeat investments, than reductions

Existing positions increased: 101 | Existing positions reduced: 58

53% more call options, than puts

Call options by funds: $13.5M | Put options by funds: $8.82M

16% more funds holding

Funds holding: 201 [Q1] → 233 (+32) [Q2]

0.61% more ownership

Funds ownership: 103.97% [Q1] → 104.57% (+0.61%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 13 [Q1] → 13 (+0) [Q2]

3% less capital invested

Capital invested by funds: $3.79B [Q1] → $3.69B (-$97.5M) [Q2]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$69

30%

upside

Avg. target

$78

47%

upside

High target

$90

69%

upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

JMP Securities Jonathan Wolleben 38% 1-year accuracy 29 / 76 met price target	51%upside $80	Market Outperform Reiterated	27 Sept 2024
Cantor Fitzgerald Josh Schimmer 54% 1-year accuracy 41 / 76 met price target	69%upside $90	Overweight Reiterated	16 Sept 2024
HC Wainwright & Co. Douglas Tsao 54% 1-year accuracy 79 / 145 met price target	30%upside $69	Buy Maintained	9 Aug 2024
Oppenheimer Leland Gershell 59% 1-year accuracy 33 / 56 met price target	37%upside $73	Outperform Reiterated	9 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about CRNX published over the past 30 days

Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on October 10, 2024, the Compensation Committee of Crinetics' Board of Directors granted non-qualified stock option awards to purchase an aggregate of 258,800 shares of its common stock to twenty-seven new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today the pricing of an upsized underwritten public offering of 10,000,000 shares of its common stock at a price to the public of $50.00 per share. All of the shares to be sold in the offering are to be sold by Crinetics. The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $500.0 million. In addition, Crinetics has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock. The offering is expected to close on or about October 10, 2024, subject to the satisfaction of customary closing conditions.

Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today that it intends to offer and sell, subject to market and other conditions, $400.0 million of shares of its common stock in a proposed underwritten public offering. In addition, Crinetics intends to grant the underwriters a 30-day option to purchase up to an additional $60.0 million of shares of common stock. All of the shares to be sold in the proposed offering are to be sold by Crinetics. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

Did this congressman benefit from a stock buy just before FDA approval?

On October 3, Representative Josh Gottheimer of New Jersey's 5th district disclosed a September 25 investment in Crinetics Pharmaceuticals (NASDAQ: CRNX), a mid-cap stock that no U.S. politician had previously traded.

Did this congressman benefit from a stock buy just before FDA approval?

Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly

SAN DIEGO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for paltusotine, the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist in development for the proposed treatment and long-term maintenance therapy of acromegaly.

Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly

Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on September 10, 2024, the Compensation Committee of Crinetics' Board of Directors granted non-qualified stock option awards to purchase an aggregate of 120,200 shares of its common stock to fifteen new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences

SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today announced that company management will participate in fireside chats at the Morgan Stanley 22nd Annual Global Healthcare Conference and the Cantor Global Healthcare Conference both being held in New York, NY in September.

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on August 10, 2024, the Compensation Committee of Crinetics' Board of Directors granted non-qualified stock option awards to purchase an aggregate of 103,900 shares of its common stock to fifteen new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals, Inc. (CRNX) Q2 2024 Earnings Call Transcript

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX ) Q2 2024 Results Conference Call August 8, 2024 4:30 PM ET Company Participants Gayathri Diwakar - Head of Investor Relations Scott Struthers - Founder and Chief Executive Officer Dana Pizzuti - Chief Medical and Development Officer Jim Hassard - Chief Commercial Officer Marc Wilson - Chief Financial Officer Alan Krasner - Chief Endocrinologist Conference Call Participants Jessica Fye - JPMorgan Yasmeen Rahimi - Piper Sandler Jeff Hung - Morgan Stanley Dennis Ding - Jefferies Joseph Schwartz - Leerink Partners Gavin Clark-Gartner - Evercore ISI Charles Moore - Baird Catherine Novack - Jones Research Jon Wolleben - Citizens JMP Leland Gershell - Oppenheimer Douglas Tsao - H.C. Wainwright Cory Jubinville - LifeSci Capital Operator Good day everyone, and welcome to the Crinetics Pharmaceuticals Second Quarter 2024 Earnings Conference Call.

Crinetics Pharmaceuticals, Inc. (CRNX) Q2 2024 Earnings Call Transcript

Zacks Investment Research

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates

Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to loss of $0.94 per share a year ago.

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates

See News Rankings

Charts implemented using Lightweight Charts™